Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
21
12
2020
accepted:
03
02
2020
pubmed:
11
3
2020
medline:
22
6
2021
entrez:
11
3
2020
Statut:
ppublish
Résumé
The fibrolamellar carcinoma-associated DNAJB1-PRKACA gene fusion transcript RNA codes for the catalytic domain of protein kinase A and, thus, overexpression of Aurora kinase A. ENMD-2076 showed a favorable toxicity profile. The limited results, one patient (3%) with a partial response and 57% of patients with stable disease, do not support further evaluation of ENMD-2076 as single agent. Future studies will depend on the simultaneous targeting approach of DNAJB1-PRKACA and the critical downstream components. Fibrolamellar carcinoma (FLC) represents approximately 0.85% of liver cancers. The associated DNAJB1-PRKACA gene fusion transcript RNA codes for the catalytic domain of protein kinase A and overexpression of Aurora kinase A (AURKA). ENMD-2076 is a selective anti-AURKA inhibitor. Patients aged >12 years with pathologically confirmed incurable FLC, with measurable disease, Eastern Cooperative Oncology Group performance status 0-2 or Lansky 70-100, and adequate organ function were eligible. Patients were prescribed ENMD-2076 based on body surface area. The primary endpoint was overall objective response rate by RECIST v1.1, with a null hypothesis of true response rate of 2% versus one-sided alternative of 15%. Secondary endpoints included 6-month progression-free survival (PFS) rate (Fig. 1), median PFS, time to progression (TTP), and overall survival (OS). Safety was evaluated throughout the study. Of 35 patients who enrolled and received treatment, 1 (3%) had a partial response (PR) and 20 (57%) had stable disease (SD). Median TTP, PFS, and OS were 5, 3.9, and 19 months, respectively. The most frequently reported drug-related serious adverse event was hypertension in three patients. Three deaths were reported on-study-two due to disease progression and one due to pulmonary embolism not related to ENMD-2076. The study provided no rationale for further studying ENMD-2076 as a single agent in FLC.
Sections du résumé
LESSONS LEARNED
The fibrolamellar carcinoma-associated DNAJB1-PRKACA gene fusion transcript RNA codes for the catalytic domain of protein kinase A and, thus, overexpression of Aurora kinase A. ENMD-2076 showed a favorable toxicity profile. The limited results, one patient (3%) with a partial response and 57% of patients with stable disease, do not support further evaluation of ENMD-2076 as single agent. Future studies will depend on the simultaneous targeting approach of DNAJB1-PRKACA and the critical downstream components.
BACKGROUND
Fibrolamellar carcinoma (FLC) represents approximately 0.85% of liver cancers. The associated DNAJB1-PRKACA gene fusion transcript RNA codes for the catalytic domain of protein kinase A and overexpression of Aurora kinase A (AURKA). ENMD-2076 is a selective anti-AURKA inhibitor.
METHODS
Patients aged >12 years with pathologically confirmed incurable FLC, with measurable disease, Eastern Cooperative Oncology Group performance status 0-2 or Lansky 70-100, and adequate organ function were eligible. Patients were prescribed ENMD-2076 based on body surface area. The primary endpoint was overall objective response rate by RECIST v1.1, with a null hypothesis of true response rate of 2% versus one-sided alternative of 15%. Secondary endpoints included 6-month progression-free survival (PFS) rate (Fig. 1), median PFS, time to progression (TTP), and overall survival (OS). Safety was evaluated throughout the study.
RESULTS
Of 35 patients who enrolled and received treatment, 1 (3%) had a partial response (PR) and 20 (57%) had stable disease (SD). Median TTP, PFS, and OS were 5, 3.9, and 19 months, respectively. The most frequently reported drug-related serious adverse event was hypertension in three patients. Three deaths were reported on-study-two due to disease progression and one due to pulmonary embolism not related to ENMD-2076.
CONCLUSION
The study provided no rationale for further studying ENMD-2076 as a single agent in FLC.
Identifiants
pubmed: 32154962
doi: 10.1634/theoncologist.2020-0093
pmc: PMC8186410
doi:
Substances chimiques
DNAJB1 protein, human
0
ENMD 2076
0
HSP40 Heat-Shock Proteins
0
Pyrazoles
0
Pyrimidines
0
Banques de données
ClinicalTrials.gov
['NCT02234986']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1837-e1845Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© AlphaMed Press; the data published online to support this summary is the property of the authors.
Références
Curr Opin Genet Dev. 2014 Feb;24:23-9
pubmed: 24657533
Science. 2014 Feb 28;343(6174):1010-4
pubmed: 24578576
Mod Pathol. 2020 Apr;33(4):648-656
pubmed: 31676785
AMA J Dis Child. 1956 Feb;91(2):168-86
pubmed: 13282629
Gastrointest Cancer Res. 2013 Jan;6(1):3-9
pubmed: 23505572
Hepatology. 2004 Mar;39(3):798-803
pubmed: 14999699
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):E5916-25
pubmed: 26489647
Mod Pathol. 2010 Sep;23(9):1180-90
pubmed: 20495535
Clin Cancer Res. 2011 Feb 15;17(4):849-60
pubmed: 21131552
Hum Mol Genet. 2015 Jan 1;24(1):50-63
pubmed: 25122662
Nat Clin Pract Oncol. 2008 Sep;5(9):531-42
pubmed: 18607391
Hepatology. 2014 Jun;59(6):2228-37
pubmed: 24443104
Surg Pathol Clin. 2018 Jun;11(2):377-387
pubmed: 29751881
Hepatology. 2018 Oct;68(4):1441-1447
pubmed: 29222914